AngioDynamics Advances Cardiovascular Pipeline with FDA Milestones and Scientific Forum
Event summary
- AngioDynamics to host its third Cardiovascular Scientific Forum from February 6–8, 2026, in Fort Lauderdale, Florida.
- Company received FDA IDE approval in November 2025 for the APEX-Return pivotal study evaluating the AlphaReturn Blood Management System.
- FDA 510(k) clearance in November 2025 expanded indications for the AlphaVac F1885 System across venous thromboembolism procedures.
- FDA IDE approval for the PAVE pilot study to evaluate the AngioVac System for right-heart vegetations in patients with right-sided infective endocarditis.
The big picture
AngioDynamics is positioning itself as a leader in minimally invasive cardiovascular treatments through strategic FDA approvals and physician-led clinical engagement. The company's focus on generating high-quality clinical evidence aligns with broader industry trends toward data-driven, patient-centric care. The recent regulatory milestones and ongoing clinical studies underscore AngioDynamics' commitment to addressing unmet needs in venous thromboembolism and right-sided infective endocarditis.
What we're watching
- Clinical Evidence Generation
- How the outcomes of the APEX-Return and PAVE studies will impact the regulatory pathway and commercial adoption of AngioDynamics' cardiovascular technologies.
- Regulatory Progress
- Whether the FDA's Breakthrough Device designation for the AngioVac System will accelerate approval timelines for other indications.
- Market Expansion
- The pace at which AngioDynamics can expand the use of its AlphaVac platform across complex venous disease treatments.
Related topics